Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(15/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(15/week)
News
United States
(1292/week)
Manufacturing
(644/week)
Energy
(504/week)
Technology
(1312/week)
Other Manufacturing
(443/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Menstruation
Jun 01, 2020
Sumitovant Biopharma Announces Myovant Sciences' Submission of New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
Mar 09, 2020
The global premenstrual syndrome treatment market was valued at $1,129 million in 2018, and is projected to reach $1,516 million by 2026, registering a CAGR of 3.7% from 2019 to 2026
Jan 31, 2020
California AB 1989 Will Allow Manufacturers of Period Care Products to Continue to Hide Ingredients
Jan 29, 2020
Adore Me introduces Joyja - an ultra-inclusive brand of period panties
Dec 04, 2019
Study Finds Key Brain Region Smaller in Birth Control Pill Users
Sep 25, 2019
Aleve® Demonstrates More Pain Relief Than Acetaminophen for Menstrual Cramps, Study Shows
May 20, 2019
Ava Unveils Unprecedented Insights Into Physical Changes During Menstrual Cycle That Can Be Used to Accurately Identify Fertile Window
Oct 08, 2018
Myovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleeding
Aug 09, 2018
Global Menstrual Cup (Disposable & Reusable) Market 2018-2022
Jul 10, 2018
Myovant Sciences Announces Completion of Screening for Phase 3 LIBERTY 1 Study Evaluating Relugolix in Women with Uterine Fibroids
Apr 24, 2018
Women's Health Company Hologic and Actor, Director Aisha Tyler Partner to Help the One in Five Women Suffering in Silence with Heavy Periods
Nov 17, 2017
Menstrual Cups Market - Global Industry Analysis, Size, Share, Trends and Forecast, 2015 - 2023
Nov 09, 2017
Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix for the Treatment of Pain Associated with Uterine Fibroids
Oct 02, 2017
Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix Compared with Leuprorelin for the Treatment of Uterine Fibroids
Latest News
May 24, 2024
Aqua Pennsylvania Files Rate Request Based on Water and Wastewater Operations, Infrastructure Improvements...
May 24, 2024
Power Integrations to Present at Upcoming Investor Conferences
May 24, 2024
Oklo Partners with Wyoming Hyperscale to Deliver 100 Megawatts to its Data Centers
May 24, 2024
NW Natural Holdings and NW Natural CEO David H. Anderson Announces Retirement
May 24, 2024
Comvest Partners Announces $70 Million Senior Credit Facility For Nationwide Energy Partners to Support...
May 24, 2024
On Elects Laura Miele as a New Independent Member of the Board of Directors
May 24, 2024
SatixFy Announces First Quarter 2024 Results
May 24, 2024
Belden Declares Quarterly Dividend
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
View All Events